US-based digital health care behavioural science and technology firm WellDoc has entered into a multi-stage collaboration with Samsung Electronics to help improve the lives of people with type 2 diabetes, as well as discover next-generation diabetes devices and product offerings.
The two parties intend to use technology to empower patient self-management and provide clinical decision-making.
Both firms commercialised unique and powerful health care platforms, which when combined, can deliver unparalleled support to patients with diabetes.
WellDoc introduced BlueStar, a mobile prescription therapy (MPT) powered by the company’s clinical and behavioural Automated Expert Analytics System.
The FDA cleared BlueStar MPT is only available with a prescription and provides real-time guidance to people with type 2 diabetes and clinical decision support for their health care provider.
By using a prior version of BlueStar in randomised controlled trials, the company showed significant clinical outcomes, achieving a 1.9-point reduction in A1C, the gold standard for measuring whether a person’s diabetes is in control.
WellDoc CEO Ryan Sysko said: "Samsung devices are an integral part of daily life for millions of people around the world, including those living with diabetes.
"At WellDoc, our mission is to support those individuals with personalised, real-time, and contextual guidance to enhance their clinical outcomes and quality of life.
"This collaboration combines the strengths of two leaders in their respective fields in an effort to make a positive impact on the global diabetes epidemic."
The Samsung digital health platform collects and integrates health information from consumer’s smartphones and other personal health devices. It also offers easy to use features in a mobile dashboard to help improve an individual’s health.